Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q3 2024 Earnings Call Transcript
Operator: Good morning, and welcome to the Axsome Therapeutics Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Axsome Therapeutics Inc. (AXSM)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Biotechnology Value Fund / BVF Inc Mark Lampert | 1,046,000 | $94,004,020 | +10% | 2.74% |
| 2. | RA Capital Management Peter Kolchinsky | 1,000,000 | $89,870,000 | 1.03% | |
| 3. | Deep Track Capital David Kroin | 857,219 | $77,038,272 | -54% | 2.44% |
| 4. | Perceptive Advisors Joseph Edelman | 782,844 | $70,354,190 | +71% | 1.48% |
| 5. | Point72 Asset Management Steve Cohen | 542,620 | $48,765,253 | +14% | 0.12% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $37.30 | 3,950 | Director | 120,756 | 2021-11-19 | Filing | |
| $35.20 | 142 | Officer | 142 | 2021-11-18 | Filing | |
| $34.30 | 145 | Officer | 145 | 2021-11-18 | Filing | |
| $35.43 | 141 | Officer | 201 | 2021-11-18 | Filing | |
| $35.50 | 527 | Officer | 41,789 | 2021-11-18 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $91.31 | 11,016 | 10,002 | 2024-09-11 | Filing | ||
| $84.26 | 47,739 | 5,783 | 2024-08-09 | Filing | ||
| $74.31 | 7,910 | 5,783 | 2024-05-29 | Filing | ||
| $75.14 | 5,248 | 14,600 | 2024-05-29 | Filing | ||
| $75.21 | 5,249 | 19,848 | 2024-05-28 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,489,596 | $357,326,946 | 5.58% | |
| 2. | 3,696,766 | $294,225,606 | 0% | |
| 3. | 3,239,746 | $257,851,385 | 0% | |
| 4. | 2,360,077 | $187,838,528 | 19.84% | |
| 5. | 924,190 | $73,556,282 | 0% |
News See All
Jim Cramer Thinks Axsome Therapeutics Inc (NASDAQ:AXSM) Stock Can Double
Jim Cramer in his latest program talked about how the China factor is affecting US stocks.
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q2 2024 Earnings Call Transcript
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q2 2024 Earnings Call Transcript August 5, 2024Axsome Therapeutics, Inc. misses on earnings expectations.
Jim Cramer Latest Portfolio: 10 Stocks to Buy and Sell
Jim Cramer in his latest program talked about how the China factor is affecting US stocks.
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q1 2024 Earnings Call Transcript
Axsome Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-1.44233 EPS, expectations were $-1.2. Axsome Therapeutics, Inc.
Wall Street Analysts See Upside Potential for 5 Stocks with Rising Price Targets
In this article, we will discuss the 10 stocks whose price targets were recently raised by analysts.
11 Oversold NASDAQ Stocks To Buy Right Now
In this article, we will be taking a look at 11 oversold NASDAQ stocks to buy right now.
11 Oversold Healthcare Stocks To Buy Right Now
In this article, we will be taking a look at 11 oversold healthcare stocks to buy right now.
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q4 2023 Earnings Call Transcript
Axsome Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-2.08 EPS, expectations were $-1.21. Axsome Therapeutics, Inc.
11 Best Upside Stocks To Buy Right Now
The art of buying shares on the market has always gone hand in hand with share price analysis. A share price, in its simplest form, is the market's estimate of the company's future.
Billionaire Hedge Funds
